John Harry Cross III serves as Executive at Sonnet BioTherapeutics Holdings, Inc., where they oversee executive responsibilities. Since joining the company, John Harry Cross III has executed 4 insider transactions totaling $0, demonstrating a balanced approach to their equity position. Their most recent transaction on Feb 6, 2023 involved selling 1,960 shares valued at $2.1K.
John Harry Cross III currently holds 23,927 shares of Sonnet BioTherapeutics Holdings, Inc. (SONN), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, John Harry Cross III has been a net neutral trader of SONN stock. They have purchased $0 and sold $0 worth of shares.
John Harry Cross III's most recent insider trade was on Feb 6, 2023, when they sold 1,960 shares at $1.06 per share.
Get notified when new Form 4 filings are submitted
| $N/A |
| Discretionary |
| Dec 15, 2021 | SONN | $0 | Award | 66,951 | $N/A | Discretionary |
| Jul 2, 2020 | SONN | $0 | Award | 78,214 | $N/A | Discretionary |